Taking advantage of the largest consecutive series of patients routinely screened for TKI-resistant mutations by NGS, we here provide a catalog of the most frequent CMs arising in Ph+ leukemias. Our real-life data show that CMs are extremely uncommon in CP-CML, although in 19 patients acquisition of a CM marked the progression to advanced phase. The prevalence of CMs increased to approximately 30% in TKI-resistant AP/BP-CML and Ph+ ALL – consistently with the much greater genetic instability of these settings.

BCR}-{ABL}1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by {NGS

Massimiliano Bonifacio;Mariella D'Adda;
2020

Abstract

Taking advantage of the largest consecutive series of patients routinely screened for TKI-resistant mutations by NGS, we here provide a catalog of the most frequent CMs arising in Ph+ leukemias. Our real-life data show that CMs are extremely uncommon in CP-CML, although in 19 patients acquisition of a CM marked the progression to advanced phase. The prevalence of CMs increased to approximately 30% in TKI-resistant AP/BP-CML and Ph+ ALL – consistently with the much greater genetic instability of these settings.
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
High-Throughput Nucleotide Sequencing
Humans
Leukemia
Philadelphia Chromosome
Prevalence
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/1049484
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact